Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Woodcock says FDA 'actively investigating' antidiabetics

FDA is actively investigating concerns that glucagon-like peptide-1 (GLP-1) receptor agonists and dipeptidyl peptidase-4 (DPP-4) inhibitors -- collectively known as incretin mimetics -- could cause pancreatitis, Janet Woodcock, director of FDA's Center for Drug Evaluation

Read the full 355 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE